Lantheus LNTH 深 沪
等待开盘 10-08 09:30:00 美东时间
100.18
+0.230
+0.23%
华盛通- 最 高100.33
- 今 开100.20
- 成交量 55.38万股
- 最 低 100.02
- 昨 收 99.95
- 总市值 65.42亿
- 52周最高 111.86
- 市盈率 静 29.36
- 换手率 0.85%
- 52周最低 50.155
- 委 比 -18.09%
- 总股本 6529.99万
- 历史最高 126.8899
- 量 比 0.61
- 振 幅 0.31%
- 历史最低 1.76
- 每 手 1
- 风险率 18.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lantheus Issues Supplemental Disclosures Ahead Curium Merger Vote
Lantheus ( ($LNTH) ) has shared an update. On August 3, 2026, Lantheus agreed t...
10-03 05:29
Lantheus Receives Transitional Pass-Through Payment Status For PYLARIFY TruVu Injection From Centers For Medicare & Medicaid Services, Effective Oct. 1
Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Centers for Medicare & Medicaid Services ("CMS") has g...
09-30 20:35
Lantheus gains approval of Bravnesta, generic competitor to Lutathera
The US FDA has granted final approval to Lantheus Holdings' (LNTH) Bravnesta (lutetium Lu 177 dotatate), a bioequivalent to Novartis' (NVS) radiopharmaceutical to Lutathera. Bravnesta is used for the ...
09-22 22:39
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
Lantheus Holdings announced the FDA approval of BRAVNETSA, a bioequivalent and therapeutically equivalent radiopharmaceutical to LUTATHERA, for treating adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This marks a significant milestone for Lantheus, expanding their radiopharmaceutical portfolio and offering new treatment options for GEP-NETs patients. BRAVNETSA was approved via the FDA's...
09-22 12:00
Lantheus withdraws, resubmits HSR filing for Curium acquisition
Lantheus Holdings (LNTH) said it has withdrawn and refiled its Hart-Scott-Rodino (HSR) Act pre-merger notification regarding its $8B acquisition of Curium. The withdrawal, done on Sept. 17, was done "...
09-22 05:35
Lantheus Merger Advances with Renewed Antitrust Review
Lantheus ( ($LNTH) ) has shared an update. On August 3, 2026, Lantheus Holdings...
09-22 04:59
朝阳门并购堂 | 2026年8月并购重组市场观察
（来源：中信建投证券投行委） 一、新增重组事件 （一）有研硅(688432.SH)停牌筹划重组 （二）雪天盐业(600929.SH) 停牌筹划重组 ...
09-16 17:09
Novartis' Lutathera now facing generic competition from Cirium's Bexlutry
The US FDA has approved Cirium's radioligand therapy Bexlutry (lutetium Lu 177 dotatate) for receptor-positive gastroenteropancreatic neuroendocrine tumors, the first such generic treatment approved f...
09-16 04:54
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
On Friday, the U.S. Food and Drug Administration (FDA) approved Lantheus Holdings Inc.’s (NASDAQ:LNTH) Tauklarify (florquinitau F 18 injection). Also known as MK-6240, this radiodiagnostic agent is designed for positron emission tomography (PET) scans of the brain in adult patients experiencing cogn...
08-15 00:11
Lantheus Holdings Announces FDA Approval Of TAUKLARIFY, Radiodiagnostic Agent Indicated For PET Of Brain In Adults For Alzheimer’s Disease
Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ ...
08-14 20:02
